Mounjaro Subcutaneous Injection

Mounjaro Subcutaneous Injection is a prescription dual GIP and GLP-1 receptor agonist containing tirzepatide that is used to improve glycemic control in adults with type 2 diabetes and, for certain formulations, to support chronic weight management. It is administered by subcutaneous injection using a sterile prefilled injection pen. The long-acting formulation provides convenient once-weekly dosing with accurate and reliable medication delivery.

BUY NOW

Category

Mounjaro Subcutaneous Injection contains tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that helps regulate blood glucose and body weight by enhancing glucose-dependent insulin secretion, reducing glucagon release, slowing gastric emptying, and promoting satiety. The once-weekly injectable formulation is delivered through a prefilled injection pen designed for precise subcutaneous administration and consistent therapeutic performance across multiple dosage strengths. Manufactured under stringent pharmaceutical quality standards, the sterile injection pen provides dependable clinical performance while supporting individualized treatment according to the prescribed dose-escalation schedule. Mounjaro Subcutaneous Injection should be used only under the supervision of a qualified healthcare professional according to the prescribed treatment plan.

Technical Specification

Specification Details
Product Name Mounjaro Subcutaneous Injection
Active Ingredient Tirzepatide
Dosage Form Sterile Prefilled Injection Pen
Route of Administration Subcutaneous Injection
Dosing Frequency Once Weekly (As Prescribed)
Storage Refrigerate at 2°C–8°C before first use

Product Also Known As

Mounjaro Subcutaneous Injection, Mounjaro Injection, Tirzepatide Subcutaneous Injection, Tirzepatide Injection Pen, Weekly Tirzepatide Injection, GIP GLP-1 Injection, Mounjaro Prefilled Pen